
    
      This single centre, open label, dose escalation study is designed to assess safety (including
      adverse events, vital signs, ECGs, and clinical laboratory tests), and pharmacokinetic
      /pharmacodynamic parameters in healthy volunteers. Subjects will attend for 3 sessions:
      session 1 is a single intravenous (IV) infusion over a short time period to confirm the
      safety of a single dose of GSK2315698 over a wide dose range, sessions 2 and 3 will
      investigate IV infusion regimens over 24 hours (induction phase followed by maintenance
      phase). The dosing regimen will be adjusted adaptively to optimise the induction and
      maintenance phases of the dosing regimen. amyloidosis.
    
  